|Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?|
B Nosyk, E Krebs, O Eyawo, JE Min, R Barrios, JSG Montaner
Current HIV/AIDS Reports 11 (4), 468-478, 2014
|Dynamics in the costs of criminality among opioid dependent individuals|
E Krebs, T Kerr, J Montaner, E Wood, B Nosyk
Drug and alcohol dependence 144, 193-200, 2014
|Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study|
B Nosyk, X Zang, JE Min, E Krebs, VD Lima, MJ Milloy, J Shoveller, ...
The lancet HIV 4 (7), e303-e310, 2017
|The costs of crime during and after publicly funded treatment for opioid use disorders: a population‐level study for the state of California|
E Krebs, D Urada, E Evans, D Huang, YI Hser, B Nosyk
Addiction 112 (5), 838-851, 2017
|Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users|
L Wang, JE Min, E Krebs, E Evans, D Huang, L Liu, YI Hser, B Nosyk
International Journal of Drug Policy 49, 32-40, 2017
|Cost-effectiveness of publicly funded treatment of opioid use disorder in California|
E Krebs, B Enns, E Evans, D Urada, MD Anglin, RA Rawson, YI Hser, ...
Annals of internal medicine 168 (1), 10-19, 2018
|Estimating state transitions for opioid use disorders|
E Krebs, JE Min, E Evans, L Li, L Liu, D Huang, D Urada, T Kerr, YI Hser, ...
Medical Decision Making 37 (5), 483-497, 2017
|Increased drug use and the timing of social assistance receipt among people who use illicit drugs|
E Krebs, L Wang, M Olding, K DeBeck, K Hayashi, MJ Milloy, E Wood, ...
Social Science & Medicine 171, 94-102, 2016
|The ‘Expanded HIV care in opioid substitution treatment’(EHOST) cluster-randomized, stepped-wedge trial: A study protocol|
B Nosyk, E Krebs, JE Min, K Ahamad, J Buxton, C Goldsmith, M Hull, ...
Contemporary clinical trials 45, 201-209, 2015
|The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study|
A Borquez, L Beletsky, B Nosyk, SA Strathdee, A Madrazo, D Abramovitz, ...
The Lancet Public Health 3 (9), e429-e437, 2018
|The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011–2013|
B Nosyk, JE Min, E Krebs, X Zang, M Compton, R Gustafson, R Barrios, ...
Clinical Infectious Diseases 66 (5), 765-777, 2017
|The costs of crime associated with stimulant use in a Canadian setting|
B Enns, E Krebs, K DeBeck, K Hayashi, MJ Milloy, L Richardson, E Wood, ...
Drug and alcohol dependence 180, 304-310, 2017
|Characterizing long-term health related quality of life trajectories of individuals with opioid use disorder|
E Krebs, T Kerr, E Wood, B Nosyk
Journal of substance abuse treatment 67, 30-37, 2016
|Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States|
B Enns, E Krebs, WC Mathews, RD Moore, KA Gebo, B Nosyk, ...
|Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?|
D Panagiotoglou, E Krebs, JE Min, M Olding, K Ahamad, L Ti, ...
International Journal of Drug Policy 47, 169-176, 2017
|Informing targeted interventions to optimize the cascade of HIV care using cluster analyses of health resource use among people living with HIV/AIDS|
E Krebs, JE Min, AM Bayoumi, R Barrios, JSG Montaner, B Nosyk, ...
AIDS and behavior 22 (1), 234-244, 2018